Evidence map›Paper›PMID 28387934›Full record

ArticleCancer2017

Effect of depression before breast cancer diagnosis on mortality among postmenopausal women.

Xiaoyun Liang, Karen L Margolis, Michael Hendryx, Katherine Reeves, Sylvia Wassertheil-Smoller, Julie Weitlauf, Suzanne C Danhauer, Rowan T Chlebowski, Bette Caan, Lihong Qi and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Depressed Mood as a Significant Risk Factor for Gynecological Cancer Aggravation.International journal of environmental research and public health · 2023
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xiaoyun LiangSchool of Social Development and Public Policy, Beijing Normal University, Beijing, China.ORCID http://orcid.org/0000-0001-6626-8091
Karen L MargolisHealthPartners Institute, Minneapolis, Minnesota.
Michael HendryxDepartment of Applied Health Science, School of Public Health, Indiana University Bloomington, Bloomington, Indiana.
Katherine ReevesDepartment of Biostatistics and Epidemiology, University of Massachusetts Amherst, Amherst, Massachusetts.
Sylvia Wassertheil-SmollerAlbert Einstein College of Medicine, Bronx, New York.
Julie WeitlaufVeterans Affairs Palo Alto Health Care System, Palo Alto, California.
Suzanne C DanhauerDepartment of Social Sciences and Health Policy, Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
Rowan T ChlebowskiLos Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California.
Bette CaanDivision of Research, Kaiser Permanente, Oakland, California.
Lihong QiDepartment of Public Health Sciences, University of California Davis, Davis, California.
Dorothy LaneDepartment of Family, Population, and Preventive Medicine, Stony Brook University School of Medicine, Stony Brook, New York.
Sayeh LavasaniMemorial Cancer Institute, Memorial Health Care System, Florida International University, Hollywood, Florida.
Juhua LuoDepartment of Epidemiology and Biostatistics, School of Public Health, Indiana University Bloomington, Bloomington, Indiana.

Funding

Women's Health Initiative Cancer Survivor CohortUM1CA173642 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ANDERSON, GARNET L., CAAN, BETTE J · 2013 to 2018
$12.1M
Life and Longevity After Cancer (LILAC): The Women's Health Initiative Cancer Survivor CohortU01CA173642 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ANDERSON, GARNET L., PASKETT, ELECTRA D. · 2019 to 2023
$7.5M
Diabetes, Metformin and Breast Cancer PrognosisR15CA179463 · NCI · TRUSTEES OF INDIANA UNIVERSITY · PI LUO, JUHUA · 2013 to 2013
$415k
NCI NIH HHS R15 CA179463NCI NIH HHS U01 CA173642NCI NIH HHS UM1 CA173642NHLBI NIH HHS HHSN268201100001INHLBI NIH HHS HHSN268201100002INHLBI NIH HHS HHSN268201100003INHLBI NIH HHS HHSN268201100004INHLBI NIH HHS HHSN268201100046CNIA NIH HHS HHSN271201100004CWHI NIH HHS HHSN268201100001CWHI NIH HHS HHSN268201100002CWHI NIH HHS HHSN268201100003CWHI NIH HHS HHSN268201100004C
6 · The paper itself

Abstract

backgroundFew previous studies investigating depression before the diagnosis of breast cancer and breast cancer-specific mortality have examined depression measured at more than 1 time point. This study investigated the effect of depression (combining depressive symptoms alone with antidepressant use) measured at 2 time points before the diagnosis of breast cancer on all-cause mortality and breast cancer-specific mortality among older postmenopausal women.

methodsA large prospective cohort, the Women's Health Initiative, was used. The study included 3095 women with incident breast cancer who had measures of depressive symptoms and antidepressant use before their diagnosis at the baseline and at year 3. Multivariate Cox proportional hazards regression was used to estimate adjusted hazard ratios (HRs) between depression at the baseline, depression at year 3, and combinations of depression at these time points and all-cause mortality and breast cancer-specific mortality.

resultsDepression at year 3 before a breast cancer diagnosis was associated with higher all-cause mortality after adjustments for multiple covariates (HR, 1.35; 95% confidence interval [CI], 1.02-1.78). There was no statistically significant association of baseline depression and all-cause mortality or breast cancer-specific mortality whether or not depression was also present at year 3. In women with late-stage (regional- or distant-stage) breast cancer, newly developed depression at year 3 was significantly associated with both all-cause mortality (HR, 2.00; 95% CI, 1.13-3.56) and breast cancer-specific mortality (HR, 2.42; 95% CI, 1.24-4.70).

conclusionsWomen with newly developed depression before the diagnosis of breast cancer had a modestly but significantly increased risk for death from any cause and for death from breast cancer at a late stage. Cancer 2017;123:3107-15. © 2017 American Cancer Society.

Indexed as

MortalityAgedAntidepressive AgentsBreast NeoplasmsCause of DeathCohort StudiesComorbidityDepressionDepressive DisorderFemaleHumansMiddle AgedMultivariate AnalysisNeoplasm StagingPostmenopauseProportional Hazards ModelsAntidepressive Agentsbreast cancerCox proportional hazards regression modeldepressionmortalitypostmenopausal women

Identifiers

PMID28387934
PMCPMC5544561

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.